The Valley Desk

NCT02202746 · Interventional trial

A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer

Overall registry status Terminated

Phase 2

Conditions Breast Cancer, ER, Estrogen Receptor Positive, HER2, HER2 Positive, MBC, Metastatic Breast Cancer, Triple Negative

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov